Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.
Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.
MD: Indiana University School of Medicine, Indianapolis, IN, 2002.
Residency: Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.
Fellowship: Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010.
Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.
Cancer and Blood Diseases, Leukemia, Fertility Preservation
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2023; 2:1151744.
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer. 2023; 70:e30271.
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.
Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. The Pediatric Infectious Disease Journal. 2023; 42:119-121.
Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy. 2023; 29:130.e1-130.e8.
262 High Disease Burden and Severe Neutropenia Predict HLH Toxicity in Patients with B-Acute Lymphoblastic Leukemia (B-ALL) Treated with Tisagenlecleucel in the PRWCC. Transplantation and cellular therapy. 2023; 29:s202-s203.
1119. Covid-19 Mab Use in High-Risk Pediatric Patients. Open Forum Infectious Diseases. 2022; 9.
Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. The Pediatric Infectious Disease Journal. 2022; 41:985-988.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances. 2022; 6:4251-4255.
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology. 2022; 40:945-955.